Interview with Ashley Frith, MD: Metastatic Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

Interview with Ashley Frith, MD: Early-Stage Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

Beyond HER2-Low: Understanding the Emerging HER2–Ultra Low Classification

View all

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

HER2 Testing in Breast Cancer - 2023 Guideline Update

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

Clinical Cancer Research

The prognostic and predictive impact of ctDNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial

Clinical Cancer Research

Real-world outcomes of elacestrant in ER+, HER2−, ESR1-mutant metastatic breast cancer

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

Breast Cancer Research

Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread

Cancer Research and Treatment

Pre-treatment Ki67 index for everolimus efficacy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer: A multicenter cohort study

HR+ HER2- Breast Cancer Resource Center

Interview with Ashley Frith, MD: Metastatic Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

HER2 Testing in Breast Cancer - 2023 Guideline Update

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

Clinical Cancer Research

The prognostic and predictive impact of ctDNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial

Clinical Cancer Research

Real-world outcomes of elacestrant in ER+, HER2−, ESR1-mutant metastatic breast cancer

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

Breast Cancer Research

Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread

Cancer Research and Treatment

Pre-treatment Ki67 index for everolimus efficacy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer: A multicenter cohort study

Journal of Surgical Oncology

Do racial and income disparities exist in the application of 21-gene recurrence score?

JAMA Oncology

Vaginal estrogen therapy use and survival in females with breast cancer

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer